Abstract
Liver injury in the HIV-positive population has been classically associated with hepatitis B or C viruses (HBV and HCV). While HBV or HCV co-infections have represented “Pillars of Hercules” for hepatic disease (not further beyond), it is now time to move forward and shed light on liver disease in HIV-infected patients without HBV or HCV co-infections. Indeed, over the last years, liver disease in HIV-mono-infected patients has emerged and fated to become one of the main non AIDS-related complications. Although several cases have specific etiologies (e.g., alcohol abuse), other cases are most challenging for the clinicians because the actual causes are only hypothesized, such as it is difficult to treat them appropriately. This new clinical entity has been named “cryptogenic” liver disease; it is polymorphic (e.g., hepatic steatosis, nodular regenerative hyperplasia or noncirrhotic portal hypertension) and multifactorial in nature, but HIV per se may play a key role. In this paper, we present a critical review of the relevant literature data, focusing on practical implications (including diagnostic tools and differential diagnosis), and delineate priorities for future research on this important topic.
Keywords: Antiretroviral therapy, HIV, liver disease, nodular regenerative hyperplasia, noncirrhotic portal hypertension, non alcoholic fatty liver disease
Current HIV Research
Title: Cryptogenic Liver Diseases: Sailing by Sight from HIV Co-Infection with Hepatitis Viruses to HIV Mono-Infection Through the Pillars of Hercules
Volume: 9 Issue: 1
Author(s): Daria Gotti, Emanuele Foca, Laura Albini, Monia Mendeni, Andrea Vavassori, Eugenia Quiros Roldan and Carlo Torti
Affiliation:
Keywords: Antiretroviral therapy, HIV, liver disease, nodular regenerative hyperplasia, noncirrhotic portal hypertension, non alcoholic fatty liver disease
Abstract: Liver injury in the HIV-positive population has been classically associated with hepatitis B or C viruses (HBV and HCV). While HBV or HCV co-infections have represented “Pillars of Hercules” for hepatic disease (not further beyond), it is now time to move forward and shed light on liver disease in HIV-infected patients without HBV or HCV co-infections. Indeed, over the last years, liver disease in HIV-mono-infected patients has emerged and fated to become one of the main non AIDS-related complications. Although several cases have specific etiologies (e.g., alcohol abuse), other cases are most challenging for the clinicians because the actual causes are only hypothesized, such as it is difficult to treat them appropriately. This new clinical entity has been named “cryptogenic” liver disease; it is polymorphic (e.g., hepatic steatosis, nodular regenerative hyperplasia or noncirrhotic portal hypertension) and multifactorial in nature, but HIV per se may play a key role. In this paper, we present a critical review of the relevant literature data, focusing on practical implications (including diagnostic tools and differential diagnosis), and delineate priorities for future research on this important topic.
Export Options
About this article
Cite this article as:
Gotti Daria, Foca Emanuele, Albini Laura, Mendeni Monia, Vavassori Andrea, Quiros Roldan Eugenia and Torti Carlo, Cryptogenic Liver Diseases: Sailing by Sight from HIV Co-Infection with Hepatitis Viruses to HIV Mono-Infection Through the Pillars of Hercules, Current HIV Research 2011; 9 (1) . https://dx.doi.org/10.2174/157016211794582597
DOI https://dx.doi.org/10.2174/157016211794582597 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial: (New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After 10 Years. Can One Study Change the Guidelines?)
Current Vascular Pharmacology Educating Scientists in Translational and Entrepreneurial Medicine: Unmet Needs and Challenges
Technology Transfer and Entrepreneurship (Discontinued) EDITORIAL: The Modulation of Signal Transduction Pathways as a Promising Therapeutic Approach to Reduce Cardiovascular Diseases
Current Signal Transduction Therapy Lipid Profile of Children Suffering from Pediatric Rheumatic Diseases (pRDS)
Current Rheumatology Reviews Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors
Current Cancer Drug Targets Diabetes and Cardiovascular Disease Following Kidney Transplantation
Current Diabetes Reviews Molecular Damage in Glaucoma: from Anterior to Posterior Eye Segment. The MicroRNA Role
MicroRNA Lifestyle Changes and Pharmacological Risk Factor Modification for Effective Vascular Disease Prevention
Vascular Disease Prevention (Discontinued) Mechanisms Underlying Beneficial Health Effects of Tea Catechins to Improve Insulin Resistance and Endothelial Dysfunction
Endocrine, Metabolic & Immune Disorders - Drug Targets Review: Evidence-based Clinical Research of Anti-obesity Supplements in Japan
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Adverse Effects of Tacrolimus in Renal Transplant Patients from Living Donors
Current Drug Safety Editorial (Thematic Issue: Myokines and Exercise Training: More Shadows than Lights)
Current Pharmaceutical Design Improved Sensory Blockade by Clonidine Added to Axillary Block Solution. Resulting Plasma Clonidine Concentration
Letters in Drug Design & Discovery Stress, Depression, Resilience and Ageing: A Role for the LPA-LPA1 Pathway
Current Neuropharmacology Nerve Growth Factor: A Focus on Neuroscience and Therapy
Current Neuropharmacology Racial Differences in Gray Matter Integrity by Diffusion Tensor in Black and White Octogenarians
Current Alzheimer Research Targeting the Renin-angiotensin System: Whats New?
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Inhibition of the Calcineurin-NFAT Signalling Cascade in the Treatment of Heart Failure
Recent Patents on Cardiovascular Drug Discovery From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network
Current Psychiatry Reviews Challenges in Oral Drug Delivery and Applications of Lipid Nanoparticles as Potent Oral Drug Carriers for Managing Cardiovascular Risk Factors
Current Pharmaceutical Biotechnology